Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Primary Care
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
Related Questions
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?
How do you manage oral ulcers as a side effect from leflunomide?
How do you handle medication refills for patients on traditional DMARDs who are lost to follow-up?
In what clinical situations do you consider azathioprine for treatment of inflammatory arthritis?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
Do you always get a baseline chest xray in patients who will be starting methotrexate?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
How do you help patients understand the difference between prolonged morning stiffness and pain?
How do you approach management of a patient with multiple lung nodules and low titer +CCP but no active joint symptoms suggestive of RA?
